Krystal Biotech (NASDAQ:KRYS) Posts Quarterly Earnings Results, Misses Expectations By $0.18 EPS

Krystal Biotech (NASDAQ:KRYS - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18), Zacks reports. The company had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%.

Krystal Biotech Trading Down 3.6 %

NASDAQ:KRYS traded down $4.94 during mid-day trading on Friday, reaching $132.23. 329,798 shares of the stock were exchanged, compared to its average volume of 300,407. Krystal Biotech has a 1-year low of $131.71 and a 1-year high of $219.34. The firm has a market capitalization of $3.82 billion, a PE ratio of 44.22 and a beta of 0.79. The business has a fifty day moving average price of $171.56 and a 200 day moving average price of $170.04.

Analyst Ratings Changes

A number of brokerages have recently issued reports on KRYS. Chardan Capital reiterated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a report on Wednesday. Guggenheim decreased their price target on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a report on Wednesday. Citigroup lifted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating and set a $240.00 price target on shares of Krystal Biotech in a report on Tuesday, May 6th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $218.63.

Insider Activity

In related news, CAO Kathryn Romano sold 750 shares of the business's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares of the company's stock, valued at approximately $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the transaction, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders own 13.70% of the company's stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).